ac investment research

Should I Buy NASDAQ:CKPT Stock? (17% Forecasted Return) | CKPT Checkpoint Therapeutics Stock Forecast



Larger, investment-grade issuers that have access to both public and private debt markets have greater flexibility than companies that depend solely on private bank loans. In addition, we consider whether a company can borrow on an unsecured basis, has access to the commercial paper markets, and issues debt in multiple geographies. It is more costly to raise debt in the public bond markets and often requires a company to establish a track record among investors. These costs and information asymmetry issues sometimes make it impractical for smaller, speculative-grade issuers to raise small amounts of debt in public markets.We believe that when a company is viewed as being on the cusp between two liquidity descriptors and has higher-than-average cash plus inventory/unadjusted debt compared with similarly constituted peers, that helps support the better liquidity assessment. However, in the case of a nonresidential developer, given that its inventory is typically less liquid (and the greater potential for inventory to suffer value erosion in a downturn), we do not consider this measure as pertinent. We estimate CKPT Checkpoint Therapeutics stock forecast parameters by: EMR with Beta because of the level of the two metrics relative to the entity's credit and market risks (17% Forecasted Return)

NASDAQ:CKPT Stock Forecast (Buy or Sell) as of 22 Jun 2022 for (n+16 weeks)

Stock: CKPT Checkpoint Therapeutics

Time series to forecast n: 22 Jun 2022 for (n+16 weeks)

x axis:Likelihood %
y axis:Potential Impact %
z axis:Color (yellow to green) Technical Analysis %

Stock Forecast Criteria and Models for CKPT Checkpoint Therapeutics

  • We typically assess factors that could restrict the flow of capital within a group to absorb losses as part of our analysis of the quality of capital and not as a quantitative adjustment to our capital measures. Such constraints may include ownership issues, regulations, and legal or tax matters.
  • We do not rate a hybrid instrument if it has a loss-absorption or cash conservation trigger that is not related to the issuer's creditworthiness.
  • A potential ICR on a group member that is lower than its SACP reflects our view that if the group or relevant government were in a credit-stress scenario, the group or government would draw resources from the group member (an example of extraordinary negative intervention), thereby weakening its creditworthiness.
  • EBITDA or revenues or other volume-based measures, as appropriate. For example, for the purposes of this calculation, we apply a "weak-link" approach to exporters. If assets are based in a high-risk country, and cannot be relocated elsewhere, we test exposure to the high-risk country, even if the products are exported to a low-risk country.
  • For prudentially regulated entities, if a hybrid can only absorb losses in a Nonviability scenario--for example, at a breach of the minimum regulatory capital standard required to maintain its license--then we assess it as having no equity content.
  • Hybrids issued by operating subsidiaries that cannot benefit the wider group in this way are treated as having no equity content in our group consolidated analysis. If, however, they can absorb losses or conserve cash at the issuer level, they are eligible for equity content in our analysis of the operating subsidiary on a stand-alone basis.
  • We make various adjustments to a financial institution's reported shareholders' funds to calculate ACE and TAC

Assumptions Underlying The Forecast Model for CKPT Checkpoint Therapeutics

In this scenario, we would still include the existing debt maturity as a use of liquidity in our A/B and A-B calculations, if the debt matures within the corresponding liquidity horizon. The rationale is that our liquidity assessment is essentially a stress test against a sudden and severe loss of capital markets access availability. For companies with an anchor of at least 'bbb-' that meet certain characteristics, as outlined in paragraphs 38 and 39 of the criteria, we may use a shorter three- to six-month time horizon when assessing upcoming maturities.

Frequently Asked QuestionsQ: Is CKPT Checkpoint Therapeutics stock buy or sell?
A: Larger, investment-grade issuers that have access to both public and private debt markets have greater flexibility than companies that depend solely on private bank loans. In addition, we consider whether a company can borrow on an unsecured basis, has access to the commercial paper markets, and issues debt in multiple geographies. It is more costly to raise debt in the public bond markets and often requires a company to establish a track record among investors. These costs and information asymmetry issues sometimes make it impractical for smaller, speculative-grade issuers to raise small amounts of debt in public markets.
Q: Is CKPT Checkpoint Therapeutics stock expected to go up?
A: We believe that when a company is viewed as being on the cusp between two liquidity descriptors and has higher-than-average cash plus inventory/unadjusted debt compared with similarly constituted peers, that helps support the better liquidity assessment. However, in the case of a nonresidential developer, given that its inventory is typically less liquid (and the greater potential for inventory to suffer value erosion in a downturn), we do not consider this measure as pertinent.
Q: What is the forecast for CKPT Checkpoint Therapeutics ?
A: In this scenario, we would still include the existing debt maturity as a use of liquidity in our A/B and A-B calculations, if the debt matures within the corresponding liquidity horizon. The rationale is that our liquidity assessment is essentially a stress test against a sudden and severe loss of capital markets access availability. For companies with an anchor of at least 'bbb-' that meet certain characteristics, as outlined in paragraphs 38 and 39 of the criteria, we may use a shorter three- to six-month time horizon when assessing upcoming maturities.
Q: What is the consensus rating of CKPT Checkpoint Therapeutics ?
A: The consensus rating for CKPT Checkpoint Therapeutics is 70.
Q: What are the risks of investing CKPT Checkpoint Therapeutics ?
A: We use risk analysis for CKPT Checkpoint Therapeutics because of the level of the two metrics relative to the entity's credit and market risks


CKPT Checkpoint Therapeutics
AC Investment Research

In our experiment, we focus on an approach known as Decision making using game theory. We apply principles from game theory to model the relationships between rating actions, news, market signals and decision making.

301 Massachusetts Avenue Cambridge, MA 02139 667-253-1000 pr@ademcetinkaya.com